ES2557407T3 - Procedimiento de imaginología de una enfermedad - Google Patents

Procedimiento de imaginología de una enfermedad Download PDF

Info

Publication number
ES2557407T3
ES2557407T3 ES11751125.3T ES11751125T ES2557407T3 ES 2557407 T3 ES2557407 T3 ES 2557407T3 ES 11751125 T ES11751125 T ES 11751125T ES 2557407 T3 ES2557407 T3 ES 2557407T3
Authority
ES
Spain
Prior art keywords
mammal
disease
phase
imaging
imaging procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11751125.3T
Other languages
English (en)
Spanish (es)
Inventor
Lloyd S. Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tau Therapeutics LLC
Original Assignee
Tau Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tau Therapeutics LLC filed Critical Tau Therapeutics LLC
Application granted granted Critical
Publication of ES2557407T3 publication Critical patent/ES2557407T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES11751125.3T 2010-03-01 2011-02-28 Procedimiento de imaginología de una enfermedad Active ES2557407T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30903010P 2010-03-01 2010-03-01
US309030P 2010-03-01
PCT/US2011/026416 WO2011109262A2 (en) 2010-03-01 2011-02-28 Cancer diagnosis and imaging

Publications (1)

Publication Number Publication Date
ES2557407T3 true ES2557407T3 (es) 2016-01-25

Family

ID=44542787

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11751125.3T Active ES2557407T3 (es) 2010-03-01 2011-02-28 Procedimiento de imaginología de una enfermedad

Country Status (13)

Country Link
US (1) US9427429B2 (enExample)
EP (1) EP2542155B1 (enExample)
JP (1) JP6017964B2 (enExample)
KR (1) KR101821343B1 (enExample)
CN (1) CN102781316B (enExample)
AU (1) AU2011223883B2 (enExample)
CA (1) CA2787673A1 (enExample)
ES (1) ES2557407T3 (enExample)
IL (1) IL221035A0 (enExample)
MX (1) MX360640B (enExample)
SG (2) SG183114A1 (enExample)
WO (1) WO2011109262A2 (enExample)
ZA (1) ZA201205377B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2576191C (en) * 2004-08-20 2013-03-19 University Of Virginia Patent Foundation T type calcium channel inhibitors
CN102781316B (zh) 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
EP3487516A1 (en) * 2016-07-19 2019-05-29 Bristol-Myers Squibb Company Radioligands for imaging the ido1 enzyme
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN110545806A (zh) 2017-02-15 2019-12-06 卡维昂公司 钙通道抑制剂
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219609A (en) 1968-07-19 1971-01-20 Koninklijke Pharma Fab Nv Diphenylmethoxyethylamino derivatives
US3732247A (en) 1970-08-14 1973-05-08 Robins Co Inc A H 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms
US4091103A (en) 1976-06-23 1978-05-23 Ciba-Geigy Corporation Quinolyl or isoquinolyl-lower-alkoxy-phenylene-amino derivatives
JPS59161392A (ja) 1983-03-04 1984-09-12 Nippon Shinyaku Co Ltd ジヒドロピリジン誘導体及びその製法
US4906646A (en) 1983-03-31 1990-03-06 Board Of Governors Of Wayne State University Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
US4885284A (en) 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
FR2601366B1 (fr) 1986-07-10 1988-11-25 Andre Buzas Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant.
DE68924456T2 (de) 1988-08-02 1996-05-30 Nissan Chemical Ind Ltd Mittel zur Verbesserung von Arzneimitteleffekten für Antitumormittel.
JP2850376B2 (ja) 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
FR2636946B1 (fr) 1988-09-23 1990-11-02 Lipha ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0467435A3 (en) 1990-07-19 1992-04-01 Akzo N.V. Benzhydryl derivatives having calmodulin inhibitor properties
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6413967B1 (en) 1995-03-30 2002-07-02 The University Of Virginia Patents Foundation Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy
CA2228604A1 (en) 1995-09-08 1997-03-13 Jan E. Schnitzer Isolation of microdomains of caveolae and gpi-anchored proteins
US5981539A (en) 1995-09-15 1999-11-09 Neurosearch A/S Piperidine compounds as calcium channel blockers
DK0882061T3 (da) 1996-02-14 2004-09-27 Isis Pharmaceuticals Inc Sukkermodificerede gapped oligonukleotider
CA2204082A1 (en) 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
US6191156B1 (en) 1997-04-11 2001-02-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating bladder dysfunction
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
EP1042468B1 (en) 1997-12-03 2006-10-18 Merck & Co., Inc. Low-voltage activated calcium channel compositions and methods
EP1036170A1 (en) 1997-12-05 2000-09-20 Loyola University Of Chicago T-type voltage-gated calcium channels and method of using same
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
JPH11246417A (ja) 1998-03-04 1999-09-14 Nissan Chem Ind Ltd 糖尿病性腎症治療用医薬組成物
JP2002525077A (ja) 1998-08-26 2002-08-13 サウス、アラバマ、メディカル、サイエンス、ファウンデーション Ｔ型カルシウムチャンネル
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6946475B1 (en) 1999-04-07 2005-09-20 University Of Virginia Patent Foundation Anticancer calcium channel blockers
ATE269848T1 (de) 1999-04-07 2004-07-15 Univ Virginia Calciumkanalblocker als antikrebsmittel
US7195783B2 (en) 1999-07-09 2007-03-27 Fx Life Sciences International Gmbh Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics
WO2001062740A1 (en) 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Mibefradil analogues and their use
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ATE357257T1 (de) 2000-07-27 2007-04-15 Pharmacia Corp Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
WO2002092127A1 (en) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
JP2005501840A (ja) 2001-07-23 2005-01-20 エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト 癌の改良された治療のための手段および方法
WO2003062421A1 (en) 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
AU2003237863A1 (en) 2002-05-20 2003-12-12 Research Development Foundation Aerosol drug inhibition of lung metastases
GB0211578D0 (en) 2002-05-21 2002-06-26 Univ Belfast Medicaments
DE10227511A1 (de) 2002-06-19 2004-01-08 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040127471A1 (en) 2002-09-17 2004-07-01 Barry Reisberg Methods of treating age associated memory impairment (AAMI), mild cognitive impairment (MCI), and dementias with cell cycle inhibitors
RU2326886C2 (ru) 2003-03-28 2008-06-20 Ниссан Кемикал Индастриз, Лтд. Блокатор кальциевых каналов т-типа
TW200528107A (en) 2003-11-25 2005-09-01 Nissan Chemical Ind Ltd T-type calcium channel inhibitor
AU2011203315B8 (en) 2004-02-11 2012-02-16 University Of Virginia Patent Foundation Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer
US20080160009A1 (en) 2004-02-11 2008-07-03 Gray Lloyd S Inhibiting Cav3 Isoforms and the 25B Splice Varients for the Diagnosis and Treatment of Cancer
EP1730173A4 (en) 2004-02-18 2008-10-08 Merck & Co Inc NUCLEIC ACID MOLECULES COORDINATING TO NEW MACHINE CALCIUM CHANNEL PROPERTIES ACTIVATED BY LOW VOLTAGES, DESCRIBED AS ALPHA 1H, PROCEDED PROTEINS, AND METHOD OF USE THEREOF
US20060003020A1 (en) 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
WO2006003020A1 (en) 2004-07-02 2006-01-12 L'oreal Compositions containing a triazine derivative, an arylalkyl benzoate derivative and a eutectic n-butylphthalimide/isopropylphthalimide mixture; cosmetic uses thereof
US20100222406A1 (en) 2007-09-11 2010-09-02 University Of Virginia Patent Foundation T Type Calcium Channel Blockers and the Treatment of Diseases
CA2576186A1 (en) 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
CA2576191C (en) 2004-08-20 2013-03-19 University Of Virginia Patent Foundation T type calcium channel inhibitors
US20120264804A1 (en) 2004-08-20 2012-10-18 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
US7851431B2 (en) 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers
KR100743255B1 (ko) 2006-05-04 2007-07-27 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체
CN101528768A (zh) * 2006-08-10 2009-09-09 肿瘤疗法科学股份有限公司 与乳腺癌相关的基因和多肽
JP5339291B2 (ja) * 2006-08-10 2013-11-13 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
US20080248033A1 (en) 2006-12-19 2008-10-09 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US20100087398A1 (en) 2007-05-02 2010-04-08 Tau Therapeutics Llc Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
WO2008141189A1 (en) 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
JP5029328B2 (ja) 2007-12-05 2012-09-19 マツダ株式会社 自動車の前部車体構造
US20110129456A1 (en) 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
KR20120030112A (ko) 2009-06-05 2012-03-27 타우 쎄라퓨틱스 엘엘씨 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법
CN102781316B (zh) 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
EP2755674A4 (en) 2011-09-12 2015-04-08 Tau Therapeutics Llc ANTAGONISTS OF PRODUCTS OF THE HS-459642-UNIGEN CLUSTER TO AVOID PROLIFERATION, DEVELOPMENT, OR DIFFERENTIATION OF STEM CELLS WITH CANCER STEM CELLS

Also Published As

Publication number Publication date
AU2011223883A1 (en) 2012-09-13
HK1179143A1 (zh) 2013-09-27
KR20130014506A (ko) 2013-02-07
SG183114A1 (en) 2012-09-27
IL221035A0 (en) 2012-09-24
JP2013521287A (ja) 2013-06-10
EP2542155B1 (en) 2015-11-04
MX2012010119A (es) 2012-09-12
US20120321561A1 (en) 2012-12-20
AU2011223883B2 (en) 2015-10-08
KR101821343B1 (ko) 2018-01-23
WO2011109262A2 (en) 2011-09-09
WO2011109262A3 (en) 2011-11-17
CN102781316A (zh) 2012-11-14
EP2542155A2 (en) 2013-01-09
US9427429B2 (en) 2016-08-30
CA2787673A1 (en) 2011-09-09
ZA201205377B (en) 2013-09-25
JP6017964B2 (ja) 2016-11-02
EP2542155A4 (en) 2013-07-17
SG10201501496TA (en) 2015-04-29
CN102781316B (zh) 2016-07-06
MX360640B (es) 2018-11-09

Similar Documents

Publication Publication Date Title
MX360640B (es) Diagnosis e imagenologia de cancer.
MX2012003551A (es) Tabletas transformables via oral.
CO2018003477A2 (es) Anticuerpos anti-pd1 y métodos de uso
UY36738A (es) Moduladores de tgr5 y métodos de uso de los mismos
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
PH12015502002B1 (en) Tripeptide epoxy ketone protease inhibitors
PH12016500024A1 (en) Bromodomain inhibitor
JO3326B1 (ar) مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد
CY1121852T1 (el) Μορφοποιησεις και μεθοδοι παρασκευης μορφοποιησεων για χρηση στον καθαρισμο του παχεος εντερου
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
EP4037659C0 (en) PHARMACEUTICAL COMPOSITION CONTAINING ENZALUTAMIDE
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
EA201490862A1 (ru) Осмотически активная система вагинальной доставки
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
CL2017002326A1 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
MX385881B (es) Forma de dosificacion de alivio prolongado
MX2017007856A (es) Composicion para el cuidado bucal.
ES2574999T3 (es) Método para la contracepción a demanda usando levonorgestrel o norgestrel
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
PT3840734T (pt) Péletes com estrutura multicamada para libertação retardada do princípio ativo no cólon distal
MX390369B (es) Inhibidores tripeptidicos de la epoxicetona proteasa
FR3014692B1 (fr) Compositions pharmaceutiques orales a retention gastrique.
CL2016002655A1 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
EP4008353A4 (en) PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION TO THE EAR